Nuclear receptors, bile-acid detoxification, and cholestasis.
Chen
Jiezhong
J
School of Pharmacy and Applied Science, Faculty of Science, Technology and Engineering, La Trobe University, Bendigo, Vic 3550, Australia.
Raymond
Kenneth
K
D000818:Animals; D001647:Bile Acids and Salts / Q000096:biosynthesis* / Q000378:metabolism; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D002779:Cholestasis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000187:drug effects* / Q000502:physiology; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D051379:Mice; D000077297:Pregnane X Receptor; D051381:Rats; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects* / Q000502:physiology; D011987:Receptors, Steroid / Q000187:drug effects* / Q000502:physiology; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D014157:Transcription Factors / Q000187:drug effects* / Q000502:physiology; D000099150:Receptor, Farnesoid X-Activated
D001647:Bile Acids and Salts; D002635:Chenodeoxycholic Acid; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors; D000077297:Pregnane X Receptor; D018160:Receptors, Cytoplasmic and Nuclear; D011987:Receptors, Steroid; D012293:Rifampin; D014157:Transcription Factors; D000099150:Receptor, Farnesoid X-Activated; C464660:obeticholic acid